Android app Apple app link

IGC adds new clinical site in Canada for Alzheimer's agitation therapy trial

By Yahoo! Finance   |   1 month ago
IGC adds new clinical site in Canada for Alzheimer's agitation therapy trial

IGC Pharma has included Hamilton Health Sciences in Canada as a new clinical site for its Phase II CALMA trial of IGC-AD1 to treat Alzheimer's-related agitation. This move aims to advance the therapy towards commercialization by evaluating its efficacy and gathering pharmacokinetic data and biomarkers.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

To become a member, please download and purchase membership through our app.